Danaher Reports Third Quarter 2026 Results

Respiratory revenue is expected to reduce fourth-quarter core revenue growth by approximately 150 basis points.

Rhea-AI Summary

Danaher (DHR) reported third-quarter 2026 revenue growth of 8.5% year over year, alongside higher earnings and increased full-year adjusted earnings guidance. Revenue reached $6.554 billion, while net earnings from continuing operations rose to $1.207 billion from $908 million. Diluted earnings per share from continuing operations were $1.71, versus $1.27. Non-GAAP adjusted diluted earnings per share increased 11.5% to $2.11.

Non-GAAP core revenue grew 3.0%, or 5.5% excluding respiratory revenue. Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion. Danaher raised its full-year adjusted diluted earnings guidance to $8.57–$8.62 per share, from $8.45–$8.60. For the fourth quarter, the company expects core revenue growth of approximately 3.0%, with growth excluding respiratory revenue of 4.0%–5.0%.

17 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Full-year adjusted diluted earnings guidance increased to $8.57–$8.62 per share, from $8.45–$8.60.
• Moderate pointThird-quarter revenue increased 8.5% year over year to $6.554 billion.
• Moderate pointThird-quarter continuing-operations net earnings reached $1.207 billion, versus $908 million a year earlier.
• Moderate pointThird-quarter diluted continuing-operations earnings rose to $1.71 per share, from $1.27 a year earlier.
• Moderate pointThird-quarter non-GAAP adjusted diluted earnings increased 11.5% year over year to $2.11 per share.
• Moderate pointThird-quarter non-GAAP core revenue increased 3.0% year over year, or 5.5% excluding respiratory revenue.
• Moderate pointThird-quarter operating profit increased to $1.245 billion, from $1.154 billion a year earlier.
• Moderate pointThird-quarter operating cash flow was $1.9 billion.
• Moderate pointThird-quarter non-GAAP free cash flow was $1.6 billion.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter non-GAAP core revenue excluding respiratory revenue is expected to grow 4.0%–5.0% year over year.

7 minor points

• Minor pointNine-month sales increased to $18.770 billion, from $17.730 billion a year earlier.
• Minor pointNine-month operating profit increased to $3.716 billion, from $3.188 billion a year earlier.
• Minor pointNine-month continuing-operations net earnings increased to $3.106 billion, from $2.417 billion a year earlier.
• Minor pointNine-month diluted continuing-operations earnings increased to $4.38 per share, from $3.37 a year earlier.
• Minor pointNine-month non-GAAP adjusted diluted earnings increased to $6.11 per share, from $5.57 a year earlier.
• Minor pointThird-quarter net discrete tax benefits totaled $263 million, primarily from reserve releases following audit settlements.
• Minor pointThird-quarter acquisition-related contingency settlement produced a $8 million pretax benefit in Life Sciences.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter respiratory revenue is expected to create an approximately 150-basis-point headwind, leaving approximately 3.0% core growth.
• Minor pointThird-quarter interest expense increased to $135 million, from $67 million a year earlier.
• Minor pointNine-month interest expense increased to $305 million, from $210 million a year earlier.
• Minor pointThird-quarter acquisition-related intangible amortization increased to $513 million pretax, from $433 million a year earlier.
• Minor pointMasimo acquisition inventory adjustments cost $84 million pretax in the quarter and $130 million over nine months.

5 minor points

• Minor pointMasimo transaction costs and pre-acquisition share-based and change-in-control payments totaled $79 million pretax over nine months.
• Minor pointBiotechnology facility impairment generated a $52 million pretax charge in the third quarter.
• Minor pointSpecial long-term growth equity awards generated $14 million pretax compensation expense in the third quarter.
• Minor pointThird-quarter investment losses were $13 million pretax, versus $15 million a year earlier.
• Minor point. Forward-looking: it has not happened yet and may not happen.Acquisition-related intangible amortization is estimated at $0.5 billion for the fourth quarter and $1.9 billion for 2026.

News Explained

The 3.0% core-growth figure excludes the separately listed 1.0% impact from tariff refunds returned to customers.

Danaher has reported third-quarter results; its 3.0% core sales growth excludes tariff refunds returned to customers, which the release lists separately as a 1.0% sales-growth impact.

The adjusted-EPS reconciliation subtracts a $0.37-per-share discrete-tax adjustment from GAAP EPS; Danaher says the quarter’s $263 million in net discrete tax benefits primarily reflects reserve releases following audit settlements.

Key Figures

Net earnings: $1.2 billion Adjusted diluted EPS: $2.11 Revenue: $6.6 billion +5 more

Net earnings

$1.2 billion

Q3 2026; up 34.5% year-over-year

Adjusted diluted EPS

$2.11

Q3 2026; grew 11.5%

Revenue

$6.6 billion

Q3 2026; increased 8.5% year-over-year

Core revenue excluding respiratory revenue

5.5%

Q3 2026 year-over-year growth, non-GAAP

Operating cash flow

$1.9 billion

Q3 2026

Free cash flow

$1.6 billion

Q3 2026, non-GAAP

Q4 core revenue outlook

4.0%–5.0%

Q4 2026 year-over-year growth excluding respiratory revenue, non-GAAP

Adjusted diluted EPS guidance

$8.57–$8.62 per share (previously $8.45–$8.60)

Full-year 2026 guidance increased

Previous Earnings Reports

2 past events · Latest: Jul 21

Same Type 2 events

1. Jul 21

   Q2 2026 earnings

   24h Move

   -11.0%

   Raised full-year adjusted EPS guidance to $8.45–$8.60 after reporting quarterly growth.

2. Oct 21

   Q3 2025 earnings

   24h Move

   +5.9%

   Reported Q3 revenue growth of 4.5% and non-GAAP core revenue growth of 3.0%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-gaap, gaap, amortization

3 terms

non-gaap financial

"this earnings release also contains non-GAAP financial measures"

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

gaap financial

"measures prepared in accordance with GAAP"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

amortization financial

"estimated amortization of acquisition-related intangible assets"

Amortization is the process of spreading a large cost over a series of future periods, either by gradually writing off the value of an intangible asset (like a patent or license) or by showing how loan principal is paid down over time. For investors it matters because amortization affects reported profits and cash flow — similar to slicing a big bill into smaller monthly payments — and therefore influences valuations, comparisons between companies, and expectations for future earnings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Third Quarter 2026 Results

• Net earnings were $1.2 billion, or $1.71 per diluted common share, up 34.5% year-over-year.
• Non-GAAP adjusted diluted net earnings per common share grew 11.5% to $2.11.
• Revenues increased 8.5% year-over-year to $6.6 billion.
• Non-GAAP core revenue excluding respiratory revenue increased 5.5% year-over-year and non-GAAP core revenue increased 3.0% year-over-year.
• Operating cash flow was $1.9 billion and non-GAAP free cash flow was $1.6 billion.

Julie Sawyer Montgomery, President and Chief Executive Officer, stated, "We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets.  The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance."

Ms. Sawyer Montgomery continued, "Danaher has built a strong foundation, and the time I've spent with our teams and customers during my transition into the CEO role has only reinforced my conviction in the opportunities ahead.  Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world."

Fourth Quarter and Full Year 2026 Outlook

Danaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the fourth quarter and $1.9 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to be flat in the fourth quarter and increase sales by 1.0% in the full year, assuming the currency exchange rates in effect as of September 25, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control.  The impact of these additional elements could be material to our results computed in accordance with GAAP.

For the fourth quarter 2026, the Company anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year.  We expect respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.

For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to $8.62 versus previous guidance of $8.45 to $8.60.

Conference Call and Webcast Information

Danaher will discuss its third quarter results and financial guidance for the fourth quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET.  The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations."  A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 800-267-6316, within the U.S. or +1 203-518-9783 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ326).  A replay of the conference call will be available shortly after the conclusion of the call and until November 4, 2026.  You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."

ABOUT DANAHER

Danaher is a leading global life sciences, diagnostics and biotechnology innovator committed to advancing the power of science and technology to improve human health. Through a connected ecosystem of industry-leading businesses, the Company works closely with customers to solve many of their most complex scientific challenges by accelerating discovery, development and the delivery of life-changing therapies. Powered by the Danaher Business System and 60,000 associates worldwide, the Company strives for continuous improvement, operational excellence and Innovation at the Speed of Life. Explore more at www.danaher.com.

NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS

In addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures.  Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the fourth quarter and full year 2026, the Company's expectations regarding business trends, opportunities, market share gains, sustainable profitable growth and improved patient outcomes and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws.  There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.  These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the acquisition of Masimo Corporation)  on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and  military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2026.  These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.

DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)
	Three-Month Period Ended				Nine-Month Period Ended
	September 25, 2026		September 26, 2025		September 25, 2026		September 26, 2025
Sales	$           6,554		$           6,053		$          18,770		$          17,730
Cost of sales	(2,717)		(2,530)		(7,731)		(7,173)
Gross profit	3,837		3,523		11,039		10,557
Operating costs:
Selling, general and administrative expenses	(2,159)		(1,991)		(6,091)		(6,209)
Research and development expenses	(433)		(378)		(1,232)		(1,160)
Operating profit	1,245		1,154		3,716		3,188
Nonoperating income (expense):
Other income (expense), net	(9)		(14)		(85)		(135)
Interest expense	(135)		(67)		(305)		(210)
Interest income	31		3		119		17
Earnings before income taxes	1,132		1,076		3,445		2,860
Income taxes	75		(168)		(339)		(443)
Net earnings from continuing operations	1,207		908		3,106		2,417
Earnings from discontinued operations, net of income taxes	28		—		28		—
Net earnings	$           1,235		$              908		$           3,134		$           2,417
Net earnings per common share from continuing operations:
Basic	$             1.71		$             1.28		$             4.40	(a)	$             3.38
Diluted	$             1.71		$             1.27		$             4.38	(a)	$             3.37
Net earnings per common share from discontinued operations:
Basic	$             0.04		$                —		$             0.04		$                —
Diluted	$             0.04		$                —		$             0.04		$                —
Net earnings per common share:
Basic	$             1.75		$             1.28		$             4.44	(a)	$             3.38	(a)
Diluted	$             1.75		$             1.27		$             4.42	(a)	$             3.37	(a)
Average common stock and common equivalent shares outstanding:
Basic	703.8		710.7		705.7		714.5
Diluted	706.8		713.7		708.5		717.9

(a)	Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.
This information is presented for reference only.  A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).

 

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Diluted Net Earnings Per Common Share from Continuing Operations and Adjusted Diluted Net Earnings Per Common Share from Continuing Operations
	Three-Month Period Ended				Nine-Month Period Ended
	September 25, 2026		September 26, 2025		September 25, 2026		September 26, 2025
Diluted Net Earnings Per Common Share From Continuing Operations (GAAP)	$           1.71		$           1.27		$           4.38		$           3.37
Amortization of acquisition-related intangible assets A	0.73		0.61		1.99		1.77
Fair value net (gains) losses on investments B	0.02		0.02		0.14		0.21
Acquisition-related items C	0.12		—		0.29		—
Impairments D	0.07		0.14		0.07		0.76
Special equity awards compensation expense E	0.02		—		0.02		—
Settlement of acquisition-related contingency F	(0.01)		—		(0.01)		—
Gain on a product line disposition G	—		—		—		(0.01)
Tax effect of the above adjustments H	(0.17)		(0.15)		(0.43)		(0.54)
Discrete tax adjustments I	(0.37)		—		(0.34)		0.02
Rounding	(0.01)		—		—		(0.01)
Adjusted Diluted Net Earnings Per Common Share From Continuing Operations (Non-GAAP)	$           2.11		$           1.89		$           6.11		$           5.57

 

Notes to Reconciliation of GAAP to Non-GAAP Financial Measures
A	Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):

	Three-Month Period Ended				Nine-Month Period Ended
	September 25, 2026		September 26, 2025		September 25, 2026		September 26, 2025
Pretax	$            513		$            433		$          1,410		$          1,269
After-tax	426		359		1,170		1,053

B	Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):

	Three-Month Period Ended				Nine-Month Period Ended
	September 25, 2026		September 26, 2025		September 25, 2026		September 26, 2025
Pretax	$             13		$             15		$             97		$            149
After-tax	10		12		74		113

C	Fair value adjustments to inventory in the three and nine-month periods ended September 25, 2026 ($84 million and $130 million pretax as reported in this line item, $67 million and $103 million after-tax, respectively), transaction costs deemed significant and pre-acquisition share-based and change-in-control payments in each case related to the acquisition of Masimo Corporation in the nine-month period ended September 25, 2026 ($79 million pretax as reported in this line item, $74 million after-tax).  The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
D	Impairment charges related to a facility in the Biotechnology segment recorded in both the three and nine-month periods ended September 25, 2026 ($52 million pretax as reported in this line item, $39 million after-tax), technology and other intangible assets in the Biotechnology segment recorded in both the three and nine-month periods ended September 26, 2025 ($86 million pretax as reported in this line item, $58 million after-tax), a trade name in the Diagnostics segment recorded in both the three and nine-month periods ended September 26, 2025 ($15 million pretax as reported in this line item, $12 million after-tax), a trade name in the Life Sciences segment recorded in the nine-month period ended September 26, 2025 ($432 million pretax as reported in this line item, $328 million after-tax) and a facility in the Biotechnology segment recorded in the nine-month period ended September 26, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).
E	Compensation expense in the three and nine-month periods ended September 25, 2026 related to special long-term growth equity awards granted to the Company's founders, certain executive officers and other key leaders in the third quarter of 2026 ("special equity awards") ($14 million pretax as reported in this line item, $14 million after-tax).  These awards have vesting terms and amounts that differ from the Company's typical annual equity grants.
F	Settlement of an acquisition-related contingency in the Life Sciences segment in the three and nine-month periods ended September 25, 2026 ($8 million pretax as reported in this line item, $6 million after-tax).
G	Gain on a product line disposition in the nine-month period ended September 26, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).
H	This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table.  In addition, the footnotes above indicate the after-tax amount of each individual adjustment item.  Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.
I	Discrete tax adjustments and other tax-related adjustments for the three-month period ended September 25, 2026, include the impact of net discrete tax benefits of $263 million related primarily to the release of reserves for uncertain tax positions resulting from audit settlements.  Discrete tax adjustments and other tax-related adjustments for the nine-month period ended September 25, 2026, include the impact of net discrete tax benefits of $242 million related primarily to the release of reserves for uncertain tax positions resulting from audit settlements and the expiration of statutes of limitations during the nine-month period, partially offset by changes in estimates associated with prior period uncertain tax positions.  There were no net discrete tax adjustments for the three-month period ended September 26, 2025, as a valuation allowance recorded on certain foreign operating losses was offset by benefits from the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change.  Discrete tax adjustments and other tax-related adjustments for the nine-month period ended September 26, 2025, include the impact of net discrete tax charges of $12 million related primarily to a valuation allowance recorded on certain foreign operating losses and changes in uncertain tax positions, partially offset by the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change and the release of reserves for uncertain tax positions due to the expiration of statutes of limitations.

 

Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding Respiratory Testing
	% Change Three-Month Period Ended September 25, 2026 vs. Comparable 2025 Period
			Segments
	Total Company		Biotechnology		Life Sciences		Diagnostics
Total sales growth (GAAP)	8.5 %		0.5 %		4.0 %		17.0 %
Impact of:
Acquisitions/divestitures	(6.5) %		— %		— %		(16.5) %
Currency exchange rates	— %		0.5 %		0.5 %		— %
Tariff refunds to customers	1.0 %		4.0 %		— %		— %
Core sales growth (non-GAAP)	3.0 %		5.0 %		4.5 %		0.5 %
Impact of respiratory testing	2.5 %						6.5 %
Core sales growth excluding respiratory testing (non-GAAP)	5.5 %						7.0 %
	% Change Nine-Month Period Ended September 25, 2026 vs. Comparable 2025 Period
			Segments
	Total Company		Biotechnology		Life Sciences		Diagnostics
Total sales growth (GAAP)	6.0 %		5.0 %		4.5 %		7.5 %
Impact of:
Acquisitions/divestitures	(3.0) %		— %		— %		(7.0) %
Currency exchange rates	(1.5) %		(1.5) %		(1.0) %		(1.0) %
Tariff refunds to customers	0.5 %		1.0 %		— %		— %
Core sales growth (decline) (non-GAAP)	2.0 %		4.5 %		3.5 %		(0.5) %
Impact of respiratory testing	2.5 %						5.5 %
Core sales growth excluding respiratory testing (non-GAAP)	4.5 %						5.0 %

Note: Beginning with the Company's Quarterly Report on Form 10-Q for the third quarter of 2026, the Company is excluding from core sales growth and core sales excluding respiratory testing the impact, if any, of tariff refunds received by the Company (related to tariff payments made in prior periods) that are returned or to be returned to customers ("tariff refunds to customers").

 

Non-GAAP Forward-Looking Information
	% Change Three- Month Period Ending December 31, 2026 vs. Comparable 2025 Period		% Change Year Ending December 31, 2026 vs. Comparable 2025 Period
Core sales growth (non-GAAP)
Biotechnology	+Mid-single digit		+Mid-single digit
Life Sciences	+4.0% - +5.0%		+3.0% - +4.0%
Diagnostics	+Up slightly		~Flat
Total Company	~+3.0%		~+2.5%
Impact of respiratory testing	~+150 basis points		+Low-single digit
Core sales growth excluding respiratory testing (non-GAAP)	+4.0% - +5.0%		+Mid-single digit

Note: For the impact of respiratory testing, a positive amount represents a year-over-year headwind to core sales growth, and a negative amount represents a year-over-year tailwind to core sales growth.

 

	Three-Month Period Ending December 31, 2026		Year Ending December 31, 2026
Adjusted operating profit margin (non-GAAP)	~29.5  %
Adjusted diluted net earnings per common share from continuing operations (non-GAAP)			$8.57 - $8.62

 

Other Forward-Looking Information
	Three-Month Period Ending December 31, 2026		Year Ending December 31, 2026
Impact of currency exchange rates on sales J	~Flat		~+1.0%
Amortization of acquisition-related intangible assets ($ in millions)	~$(500)		~$(1,900)
Corporate expense K ($ in millions)	~$(90)		~$(355)
Interest expense, net L ($ in millions)	~$(120)		~$(305)
Effective tax rate	~17.0  %		~17.0  %
Average adjusted diluted shares (in millions)	~707		~708

J	Impact of currency exchange rates on sales for the fourth quarter and full year 2026 assumes the currency exchange rates in effect as of September 25, 2026.
K	Corporate expense represents the operating profit (GAAP) for the Company's Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance, less approximately $200 million in both periods of stock-based compensation expense associated with the special equity awards, which is inclusive in both periods of a $185 million charge related to certain of the special equity awards that have been canceled.
L	Interest expense, net is defined as interest expense net of interest income.  This line item is an assumption rather than a forecast.  The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of September 25, 2026 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding.

 

Historical Sales (Decline) Growth, Core Sales Growth and Core Sales Growth Excluding Respiratory Testing
	% Change Three-Month Period Ended vs. Comparable 2024 Period								% Change Year Ended December 31, 2025 vs. Comparable 2024 Period		% Change Three-Month Period Ended vs. Comparable 2025 Period
	March 28, 2025		June 27, 2025		September 26, 2025		December 31, 2025				March 27, 2026		June 26, 2026
Total sales (decline) growth (GAAP)	(1.0) %		3.5 %		4.5 %		4.5 %		3.0 %		3.5 %		5.5 %
Impact of:
Acquisitions /divestitures	(0.5) %		— %		— %		0.5 %		— %		— %		(1.5) %
Currency exchange rates	1.5 %		(2.0) %		(1.5) %		(2.5) %		(1.0) %		(3.0) %		(1.0) %
Core sales growth (non-GAAP)	— %		1.5 %		3.0 %		2.5 %		2.0 %		0.5 %		3.0 %
Impact of respiratory testing	1.0 %		0.5 %		(0.5) %		1.5 %		0.5 %		2.5 %		1.5 %
Core sales growth excluding respiratory testing (non-GAAP)	1.0 %		2.0 %		2.5 %		4.0 %		2.5 %		3.0 %		4.5 %

Note: For the impact of respiratory testing, a positive amount represents a year-over-year headwind to core sales growth, and a negative amount represents a year-over-year tailwind to core sales growth.

 

Historical and Forward-Looking Respiratory Testing Sales

($ in millions)

Three-Month Period Ended

Year Ended December 31, 2025 M

Three-Month Period Ended

Three- Month Period Ending December 31, 2026

Year Ending December 31, 2026

March 28, 2025

June 27, 2025

September 26, 2025

December 31, 2025

March 27, 2026

June 26, 2026

September 25, 2026

Respiratory testing sales N

~$650

~$300

~$500

~$500

~$1,900

~$500

~$250

~$350

~$400

~$1,500

M	Respiratory testing sales amounts for the relevant three-month periods may not add to the year-to-date period amount due to rounding.
N	Actual respiratory testing sales are rounded to the nearest $50 million.

 

Cash Flow from Continuing Operations, Free Cash Flow from Continuing Operations and Related Measures
($ in millions)
	Three-Month Period Ended				Year-over- Year Change		Nine-Month Period Ended				Year-over- Year Change
	September 25, 2026		September 26, 2025				September 25, 2026		September 26, 2025
Total Cash Flow from Continuing Operations:
Net cash provided by operating activities from continuing operations (GAAP)	$       1,886		$       1,662				$        4,742		$       4,299
Total cash used in investing activities for continuing operations (GAAP)	$        (300)		$         (312)				$     (10,696)		$        (812)
Total cash (used in) provided by financing activities for continuing operations (GAAP)	$        (262)		$      (2,781)				$        7,057		$      (4,283)
Free Cash Flow from Continuing Operations:
Net cash provided by operating activities from continuing operations (GAAP)	$       1,886		$       1,662		~ 13.5  %		$       4,742		$       4,299		~ 10.5  %
Less: payments for additions to property, plant & equipment (capital expenditures) (GAAP)	(255)		(292)				(761)		(785)
Plus: proceeds from sales of property, plant & equipment (capital disposals) (GAAP)	1		—				1		10
Free cash flow from continuing operations (non-GAAP)	$       1,632		$       1,370		~ 19.0  %		$       3,982		$       3,524		~ 13.0  %
Operating Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio:
Net cash provided by operating activities from continuing operations (GAAP)	$       1,886		$       1,662				$       4,742		$       4,299
Net earnings from continuing operations (GAAP)	1,207		908				3,106		2,417
Operating cash flow from continuing operations to net earnings from continuing operations conversion ratio (GAAP)	1.56		1.83				1.53		1.78
Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio:
Free cash flow from continuing operations from above (non-GAAP)	$       1,632		$       1,370				$       3,982		$       3,524
Net earnings from continuing operations (GAAP)	1,207		908				3,106		2,417
Free cash flow from continuing operations to net earnings from continuing operations conversion ratio (non-GAAP)	1.35		1.51				1.28		1.46

We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment ("capital expenditures") plus the proceeds from sales of plant, property and equipment ("capital disposals").

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies.  Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:

• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers;
  
  
• with respect to the non-GAAP measures related to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and
  
  
• with respect to free cash flow (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).

Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share From Continuing Operations, Adjusted Operating Profit and the FCF Measure in the Company's executive compensation program.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

• With respect to the profitability-related non-GAAP measures:
  
  
  • Amortization of Intangible Assets:  We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate.  While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition.  Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies.  We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized.
    
    
  • Restructuring Charges:  We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System.  Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time.
    
    
  • Other Adjustments:  With respect to the other items excluded from the profitability-related non-GAAP measures, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult. 
    
    
• With respect to core sales and core sales excluding respiratory testing, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult and (3) beginning with the Company's Quarterly Report on Form 10-Q in the third quarter of 2026, we exclude tariff refunds to customers to help customers better understand underlying growth trends in the Company's business that otherwise may be obscured by such item.
  
  
• With respect to core sales excluding respiratory testing, we exclude the impact of revenues related to the sale of respiratory testing products in the Company's molecular diagnostics business in the Diagnostics segment.  Demand for respiratory testing depends significantly on the severity levels of influenza and influenza-like illness in a given period, and these severity levels are not under management's control.  As a result, presenting core sales on a basis that combines respiratory testing revenue with other Diagnostics business revenues can obscure underlying growth trends within the Diagnostics businesses.  The Company believes that this measure complements core sales, enhances investors' understanding of the historical and anticipated performance of the Diagnostics businesses as a whole, including with respect to underlying growth trends and facilitates comparisons of period-to-period performance. 
  
  
• With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements.

View original content:https://www.prnewswire.com/news-releases/danaher-reports-third-quarter-2026-results-302914824.html

SOURCE Danaher Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Danaher's third-quarter 2026 revenue and earnings?

Danaher reported $6.554 billion in revenue and $1.71 in diluted earnings per share from continuing operations for the third quarter of 2026. Revenue increased 8.5% year over year. Non-GAAP adjusted diluted earnings per share increased 11.5% to $2.11.

What is Danaher's updated 2026 earnings guidance?

Danaher raised its full-year 2026 non-GAAP adjusted diluted earnings guidance to $8.57–$8.62 per share, compared with its previous range of $8.45–$8.60.

How did tax adjustments affect Danaher's third-quarter 2026 results?

Danaher's third-quarter results included $263 million in net discrete tax benefits, primarily from releasing reserves for uncertain tax positions following audit settlements. The adjusted earnings reconciliation removes these benefits through a $0.37-per-share discrete tax adjustment.

What Masimo acquisition costs did Danaher record in 2026?

Danaher recorded Masimo-related inventory fair-value adjustments of $84 million pretax in the third quarter and $130 million pretax over nine months. Transaction costs and pre-acquisition share-based and change-in-control payments related to the acquisition totaled $79 million pretax over the nine-month period.